HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering - PubMed
9 hours ago
- #OX40 immunotherapy
- #Affinity optimization
- #Treg depletion
- HFB301001 is a low-affinity OX40 agonist antibody that induces stronger receptor clustering, enhances T-cell activation, and provides better Treg clearance via NK cell-mediated ADCC than its high-affinity mutant.
- In murine tumor models, HFB301001 improved anti-tumor efficacy by increasing intratumoral T-cell infiltration/activation and clearing regulatory T cells.
- HFB301001 demonstrated favorable safety in cynomolgus monkeys and effectively activated tumor-infiltrating T cells in a clinically relevant tumor slice culture system.
- The study suggests a reduced-affinity strategy may optimize OX40-targeted immunotherapies, with HFB301001 currently in a phase I trial for advanced solid tumors (NCT05229601).